MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma.

Liantao LiNa LiNianli LiuFuchun HuoJunnian Zheng

Published in: OncoTargets and therapy (2020)

These results indicated that MBD2confers an oncogenic function in the malignant progression of RCC. MBD2 could be served as a meaningful prognostic biomarker and a latent therapeutic target in RCC patients.

Keyphrases

poor prognosis
renal cell carcinoma
long non coding rna
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
transcription factor
patient reported outcomes